Gwendolyn Wu's articles Biotechnology Boundless Bio breaks IPO lull with $100M fundraise The startup’s efficiency will check buyers’ urge for food for early-stage drugmakers, as Boundless has solely superior so far as Section 1 medical trials. Written by Gwendolyn Wu March 29, 2024March 29, 2024 Saving Bookmark this article Bookmarked Biotechnology Laronde, Senda Biosciences merge to create new Flagship company The troubled RNA biotech is merging with Senda, another Flagship company that has drawn hundreds of millions of dollars in investment. Written by Gwendolyn Wu October 20, 2023October 20, 2023 Saving Bookmark this article Bookmarked
Biotechnology Boundless Bio breaks IPO lull with $100M fundraise The startup’s efficiency will check buyers’ urge for food for early-stage drugmakers, as Boundless has solely superior so far as Section 1 medical trials. Written by Gwendolyn Wu March 29, 2024March 29, 2024 Saving Bookmark this article Bookmarked
Biotechnology Laronde, Senda Biosciences merge to create new Flagship company The troubled RNA biotech is merging with Senda, another Flagship company that has drawn hundreds of millions of dollars in investment. Written by Gwendolyn Wu October 20, 2023October 20, 2023 Saving Bookmark this article Bookmarked
